Literature DB >> 19628565

Co-expression of PDGF-B and VEGFR-3 strongly correlates with lymph node metastasis and poor survival in non-small-cell lung cancer.

T Donnem1, S Al-Saad, K Al-Shibli, L-T Busund, R M Bremnes.   

Abstract

BACKGROUND: Platelet-derived growth factors (PDGFs) and vascular endothelial growth factors and their receptors [platelet-derived growth factor receptors (PDGFRs) and vascular endothelial growth factor receptors (VEGFRs)] are related to both angiogenesis and lymphangiogenesis and are important targets in new cancer treatment strategies. We aimed to study the PDGFs/PDGFRs and correlations with lymph node metastasis (LNM) and investigate the prognostic impact of the co-expression of PDGF-B and VEGFR-3 and its correlation with LNM. PATIENTS AND METHODS: Tumor tissue samples from 335 resected patients with stage I-IIIA non-small-cell lung cancer (NSCLC) were obtained and tissue microarrays were constructed from duplicate cores of tumor cells and tumor-related stroma from each specimen. Immunohistochemistry was used to evaluate the expression of the molecular markers PDGF-A, PDGF-B, PDGF-C, PDGF-D, PDGFR-alpha, PDGFR-beta, VEGFR-3 and D2-40.
RESULTS: There were 232 N0 and 103 N+ patients (76 N1 and 27 N2). In multivariate analyses, high tumor cell PDGF-A expression (P = 0.017) correlated with LNM. Tumor cell co-expression of VEGFR-3 and PDGF-B correlated with nodal metastasis and was an independent indicator of poor prognosis (hazard ratio 4.8, confidence interval 95% 2.80-8.31, P < 0.001).
CONCLUSION: Tumor cell PDGF-A expression correlates with LNM, and the co-expression of PDGF-B and VEGFR-3 is strongly associated with poor survival in NSCLC patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19628565     DOI: 10.1093/annonc/mdp296

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  33 in total

Review 1.  Adding to the mix: fibroblast growth factor and platelet-derived growth factor receptor pathways as targets in non-small cell lung cancer.

Authors:  S A Kono; L E Heasley; R C Doebele; D R Camidge
Journal:  Curr Cancer Drug Targets       Date:  2012-02       Impact factor: 3.428

2.  [Screening key genes associated with the development and progression of non-small cell lung cancer based on gene-enrichment analysis and meta-analysis].

Authors:  Wenwu He; Lei Xian; Yongyong Wang; Yanling Hu; Mingwu Chen
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2012-07

3.  E2F1 promotes angiogenesis through the VEGF-C/VEGFR-3 axis in a feedback loop for cooperative induction of PDGF-B.

Authors:  David Engelmann; Deborah Mayoli-Nüssle; Christian Mayrhofer; Katharina Fürst; Vijay Alla; Anja Stoll; Alf Spitschak; Kerstin Abshagen; Brigitte Vollmar; Sophia Ran; Brigitte M Pützer
Journal:  J Mol Cell Biol       Date:  2013-09-06       Impact factor: 6.216

4.  Molecular signature and pathway analysis of human primary squamous and adenocarcinoma lung cancers.

Authors:  Nikolai Daraselia; Yipeng Wang; Adam Budoff; Alexander Lituev; Olga Potapova; Gordon Vansant; Joseph Monforte; Ilya Mazo; Valeria S Ossovskaya
Journal:  Am J Cancer Res       Date:  2011-11-19       Impact factor: 6.166

5.  MiR-106a is an independent prognostic marker in patients with glioblastoma.

Authors:  Shiguang Zhao; Guang Yang; Yulong Mu; Dayong Han; Chen Shi; Xin Chen; Yifan Deng; Daming Zhang; Lu Wang; Yaohua Liu; Xu Hou; Chunlei Wang; Jianing Wu; Huailei Liu; Ligang Wang; Guang Zhang; Jiping Qi; Xiang Fang; Changbin Shi; Jing Ai
Journal:  Neuro Oncol       Date:  2013-02-14       Impact factor: 12.300

6.  Synergistic interaction between sunitinib and docetaxel is sequence dependent in human non-small lung cancer with EGFR TKIs-resistant mutation.

Authors:  Feng Pan; Jing Tian; Xuchao Zhang; Ying Zhang; Yueyin Pan
Journal:  J Cancer Res Clin Oncol       Date:  2011-07-28       Impact factor: 4.553

Review 7.  HIF, hypoxia and the role of angiogenesis in non-small cell lung cancer.

Authors:  Autumn L Jackson; Bing Zhou; William Y Kim
Journal:  Expert Opin Ther Targets       Date:  2010-10       Impact factor: 6.902

Review 8.  Targeting angiogenesis in squamous non-small cell lung cancer.

Authors:  Bilal Piperdi; Amartej Merla; Roman Perez-Soler
Journal:  Drugs       Date:  2014-03       Impact factor: 9.546

Review 9.  An update on molecularly targeted therapies in second- and third-line treatment in non-small cell lung cancer: focus on EGFR inhibitors and anti-angiogenic agents.

Authors:  M Majem; C Pallarès
Journal:  Clin Transl Oncol       Date:  2013-01-29       Impact factor: 3.405

10.  The overexpression of PDGF-BB and its receptor is correlated with lymphatic metastasis in patients with non-small cell lung cancer.

Authors:  Ning Zhang; Huixian Hu; Yongqiang Fu; Fang He; Lili Wang; Shunhong Zhuang; Mingxing Ding
Journal:  Int J Clin Exp Pathol       Date:  2018-12-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.